SeaBeLife develops innovative drugs to treat severe diseases involving regulated necrosis without effective treatments. Our patented molecules stop cell death protecting organs through an original mechanism of action. The therapeutic and economic potential is major, as regulated necrosis plays a key role in the pathogenesis of severe diseases: acute liver or kidney failure, cardiac and cerebral ischemia, neurodegenerative diseases and dry-AMD.